Wake Forest University

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Wake Forest University sits in the top decile of US sponsors by registered trial count (#240 of 15,742 sponsors by registered trial count).

100 total trials 7 currently recruiting 74 completed top decile by trial count

Wake Forest University: 100 sponsored US clinical trials, 7 recruiting.

Wake Forest University sponsors 100 registered US clinical trials on ClinicalTrials.gov, 7 of them currently recruiting, and 74 completed. 22 of these trials are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Urinary Incontinence, with 2 trials.

Top-decile sponsor footprint

Wake Forest University ranks in the top decile of sponsors by registered trial count (#240 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 40/100

74 of 92 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

100 total, page 2 of 2

COMPLETED NA

A Comparison of Different Ventilation Strategies in Infants Using the PLMA™

NCT03235817

COMPLETED Early Phase 1

Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy

NCT01306838

COMPLETED NA

Standardized Rehabilitation for Intensive Care Unit (ICU) Patients With Acute Respiratory Failure

NCT00976833

COMPLETED NA

Physical and Cognitive Function - Look AHEAD Ancillary Study

NCT01410097

TERMINATED Phase 4

Tetracaine Combined Spinal Epidural (CSE) Versus Bupivacaine CSE

NCT01005459

COMPLETED

Xience V at Wake Forest University Baptist Medical Center (WFUBMC)

NCT00937573

COMPLETED NA

A Novel Method to Improve Acne Outcomes

NCT01176955

TERMINATED

The Effect of Levocetirizine on Inflammatory Mediators in Dermatographism

NCT01008592

COMPLETED Phase 4

Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris

NCT01047189

COMPLETED NA

Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema

NCT00790803

COMPLETED NA

Exercise Intolerance in Elderly Patients With Diastolic Heart Failure

NCT00959660

TERMINATED

A 5 Year Follow-up on Newly Diagnosed Breast Cancer Patients

NCT01176838

COMPLETED Phase 1

Epidural Neostigmine for Labor Pain

NCT00779467

COMPLETED NA

The Effects of Music Therapy on Women's Anxiety Before and During Cesarean Delivery

NCT01049477

COMPLETED NA

Fixation of Unstable Distal Radius Fractures

NCT00654615

COMPLETED Phase 4

Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis

NCT00655564

COMPLETED Phase 4

Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit

NCT00654355

TERMINATED Phase 2

Effect of Spinal Ketorolac on Mechanical Hypersensitivity After a Total Hip Replacement

NCT00621530

COMPLETED Phase 4

Ethnic Differences in Response to Topical Capsaicin: A Psychophysical Study on Healthy Subjects

NCT00655811

TERMINATED Phase 4

Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy

NCT00619983

TERMINATED Phase 2

Rhubarb and Angiotensin Converting Enzyme Inhibitor

NCT00672451

TERMINATED Phase 2

Effect of Spinal Ketorolac After Acute Opioid Exposure

NCT00693160

COMPLETED Phase 4

Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis

NCT00690833

TERMINATED

Severity Postoperative Pain Prediction

NCT00638404

COMPLETED NA

Effect Of Acute Inflammatory Mediators On Functional Limitations In Patients With Acute Respiratory Failure

NCT01707303

COMPLETED NA

Physical Activity Program for Older Renal Transplant Candidates

NCT00857974

COMPLETED NA

Compatibility of a Mild, Moisturizing Hand Cleanser for Patients With Mild to Moderate Hand Dermatitis

NCT00843466

COMPLETED

Evaluation of Scalp and Hair Shaft With Biologic Markers in African American and Caucasian Hair

NCT00690664

COMPLETED Phase 4

Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population

NCT00696488

TERMINATED

Structural Analysis of Human Tissue

NCT01293864

COMPLETED

Comprehensive Investigation of Heart Rate Variability as a Measure of the Autonomic Nervous System in Atopic Dermatitis

NCT00691366

COMPLETED Phase 4

Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis

NCT00693693

COMPLETED Phase 4

Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients

NCT00693654

COMPLETED Phase 4

Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy

NCT00695578

COMPLETED NA

Intensive Diet and Exercise for Improving Knee Osteoarthritis in Obese and Overweight Older Adults

NCT00381290

COMPLETED Phase 4

Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne

NCT00658112

COMPLETED Phase 4

Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris

NCT00696449

TERMINATED Phase 4

Effects of Capsaicin on the Structure, Distribution, and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin

NCT00697034

COMPLETED

Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia

NCT00691769

COMPLETED

Comprehensive Investigation of Opiates, Neuropeptides, Barrier Function, Scratching and Sleep Physiology

NCT00696397

COMPLETED NA

Benefits of Tanning in Fibromyalgia Patients

NCT00447083

COMPLETED Phase 3

PIE II: Pharmacological Intervention in the Elderly II

NCT00123955

COMPLETED Phase 4

Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage

NCT00314756

COMPLETED Phase 2

Thalidomide in the Treatment of Chronic Plaque Psoriasis.

NCT01891019

COMPLETED Phase 3

Cognition in the Study of Tamoxifen and Raloxifene

NCT00687102

COMPLETED Phase 2

Macrolide Antibiotic Therapy for Patients With Cystic Fibrosis

NCT00205634

COMPLETED

Women's Health Initiative Study of Cognitive Aging

NCT00631332

COMPLETED Phase 2

Study of Expectorant Activity of Oral N-acetylcystein (NAC) in Patients With Stable Chronic Bronchitis

NCT00205647

COMPLETED Phase 3

Post-hospitalization Nursing Effectiveness (PHONE) Study

NCT00314431

COMPLETED NA

Prospective Aerobic Reconditioning Intervention Study

NCT01113840

← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 10
Phase 3 3
Phase 4 19

What is open in the Wake Forest University pipeline

7 recruiting of 100 indexed (7% open); 74 completed (74%).

Phase mix: 22 late (III/IV) vs 15 early (I/II) (balanced across stages).

Top condition: Urinary Incontinence (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Wake Forest University: open-pipeline peers nationwide

Peers matched on 100 registered trials and 7% open enrollment, not the therapeutic-area sidebar.

Wake Forest University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400 0%5%10%15%20% Total trials Recruiting share Wake Forest UniversityUCB PharmaSpaulding Rehabilitation HospitalGE HealthcareJohnson & Johnson Pharmaceutical Research & Development, L.L.C.H. Lundbeck A/SGenentechState University of New York - Upstate Medical UniversityBioCryst Pharmaceuticals
Wake Forest University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Wake Forest University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 100 trials (± recruiting share)

Sponsors near 7% open enrollment (± trial volume)

What to do with this Wake Forest University page

100 registered trials is a research-attention snapshot, not an endorsement of Wake Forest University or any single study.

  • 7 of Wake Forest University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Urinary Incontinence is the condition Wake Forest University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Urinary Incontinence trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Wake Forest University pipeline card: 100 registered trials from official public datasets.Report a data error.